



What is claimed is:


1. Use of a compound of formula I



wherein G is either not present, lower alkylene or C₃-C₅cycloalkylene and Z is a radical of the formula Ia



or G is not present and Z is a radical of the formula Ib



A is CH, N or N→O and A' is N or N→O, with the proviso that not more than one of A and A' can be N→O;

n is 1 or 2;

m is 0, 1 or 2;

p is 0, 2 or 3;

r is 0 to 5;

X is NR if p is 0, wherein R is hydrogen or an organic moiety, or if p is 2 or 3, X is nitrogen which together with (CH₂)_p and the bonds represented in dotted (interrupted) lines (including the atoms to which they are bound) forms a ring,

or

X is CHK wherein K is lower alkyl or hydrogen and p is zero,

with the proviso that the bonds represented in dotted lines, if p is zero, are absent;

Y₁ is O, S or CH₂;

Y₂ is O, S or NH;

with the proviso that (Y₁)_n-(Y₂)_m does not include O-O, S-S, NH-O, NH-S or S-O groups;

each of R₁, R₂, R₃ and R₅, independently of the others, is hydrogen or an inorganic or organic moiety or any two of them together form a lower alkylene-dioxy bridge bound via the oxygen atoms, and the remaining one of these moieties is hydrogen or an inorganic or organic moiety;

and R₄ (if present, that is, if r is not zero) is an inorganic or organic moiety;

or a tautomer thereof;

or a pharmaceutically acceptable salt thereof;

for the manufacture of a pharmaceutical composition for the treatment of a RET dependent disease.

2. The use according to claim 1, wherein the RET dependent disease is a RET dependent tumour disease.

3. The use according to claim 2, wherein the RET dependent tumour disease is selected from colon cancer, lung cancer, breast cancer, pancreatic cancer and thyroid cancer.

4. The use according to claim 3, wherein the cancer is thyroid cancer.

5. An N-[4-(pyrimidin-4-yloxy)-phenyl]-N'-phenyl-urea derivative selected from the group consisting of the compounds of Examples 1 - 67 , 68 - 70 or 71 - 95 as described in the description, or a salt thereof.

6. A pharmaceutical composition comprising an N-[4-(pyrimidin-4-yloxy)-phenyl]-N'-phenyl-urea derivative selected from the group consisting of the compounds of Examples 1 - 67 , 68 - 70 or 71 - 95 as described in the description, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7. An N-[4-(pyrimidin-4-yloxy)-phenyl]-N'-phenyl-urea derivative selected from the group consisting of the compounds of Examples 1 - 67 , 68 - 70 or 71 - 95 as described in the description, or a pharmaceutically acceptable salt thereof, for use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease.
8. A compound according to claim 7, where the protein kinase dependent disease to be treated is a protein tyrosine kinase dependent disease, especially a proliferative disease depending on any one or more of the following protein tyrosine kinases: c-Abl, Bcr-Abl, Flt-3, RET, VEGF-R and/or Tek, especially Flt-3.
9. Use of an N-[4-(pyrimidin-4-yloxy)-phenyl]-N'-phenyl-urea derivative selected from the group consisting of the compounds of Examples 1 - 67 , 68 - 70 or 71 - 95 as described in the description, or a pharmaceutically acceptable salt thereof, for use in the treatment of a protein kinase dependent disease.
10. Use of an N-[4-(pyrimidin-4-yloxy)-phenyl]-N'-phenyl-urea derivative selected from the group consisting of the compounds of Examples 1 - 67 , 68 - 70 or 71 - 95 as described in the description, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for use in the treatment of a protein kinase dependent disease.
11. The use according to claim 9 or 10 where the protein kinase dependent disease is a protein tyrosine kinase dependent disease, especially a proliferative disease depending on any one or more of the following protein tyrosine kinases: c-Abl, Bcr-Abl, Flt-3, RET, VEGF-R and/or Tek, especially Flt-3.
12. A method of treatment for a disease that responds to inhibition of a (especially tyrosine) protein kinase which comprises administering a prophylactically or especially therapeutically effective amount of an N-[4-(pyrimidin-4-yloxy)-phenyl]-N'-phenyl-urea derivative selected from the group consisting of the compounds of Examples 1 - 67 , 68 - 70 or 71 - 95 as described in the description, or a pharmaceutically acceptable salt thereof, to a warm-blooded animal, for example a human, in need of such treatment.